Expression of Trpa1 and Trpv1 Genes in the Hypothalamus and Blood Pressure in Normotensive and Hypertensive Rats. Effect of Losartan and Captopril
Analysis of the role of genomic regulation of systolic BP (SBP) in normal and hypertensive rats showed the presence of an inverse relationship between the level ofTrpa1 gene expression in the anterior hypothalamus and SBP. Losartan, an antagonist of angiotensin II type 1 receptors, shifts it to the region of lower SBP and greater expression of theTrpa1 gene, which can attest to interaction of the TRPA1 ion channel in the anterior hypothalamus with angiotensin II type 1 receptors. No association was found between the expression of theTrpv1 gene in the hypothalamus and SBP. We have previously shown that activation of the per...
Source: Bulletin of Experimental Biology and Medicine - March 7, 2023 Category: Biology Source Type: research
Venoms classification and therapeutic uses: a narrative review
Eur Rev Med Pharmacol Sci. 2023 Feb;27(4):1633-1653. doi: 10.26355/eurrev_202302_31408.ABSTRACTThe mere glimpse of venomous animals has always terrified humans because of the devastating effects of their venoms. However, researchers across the globe have isolated therapeutically active ingredients from these venoms and continue to explore them for drug leads. These efforts lead to the discovery of therapeutic molecules that the US-FDA has approved to treat different diseases, such as hypertension (Captopril), chronic pain (Ziconotide), and diabetes (Exenatide). The main active constituents of most venoms are proteins and p...
Source: Pharmacological Reviews - March 6, 2023 Category: Drugs & Pharmacology Authors: M A Morsy S Gupta C P Dora V Jhawat M Dhanawat D Mehta K Gupta A B Nair M El-Daly Source Type: research
Venoms classification and therapeutic uses: a narrative review
Eur Rev Med Pharmacol Sci. 2023 Feb;27(4):1633-1653. doi: 10.26355/eurrev_202302_31408.ABSTRACTThe mere glimpse of venomous animals has always terrified humans because of the devastating effects of their venoms. However, researchers across the globe have isolated therapeutically active ingredients from these venoms and continue to explore them for drug leads. These efforts lead to the discovery of therapeutic molecules that the US-FDA has approved to treat different diseases, such as hypertension (Captopril), chronic pain (Ziconotide), and diabetes (Exenatide). The main active constituents of most venoms are proteins and p...
Source: European Review for Medical and Pharmacological Sciences - March 6, 2023 Category: Drugs & Pharmacology Authors: M A Morsy S Gupta C P Dora V Jhawat M Dhanawat D Mehta K Gupta A B Nair M El-Daly Source Type: research
Venoms classification and therapeutic uses: a narrative review
Eur Rev Med Pharmacol Sci. 2023 Feb;27(4):1633-1653. doi: 10.26355/eurrev_202302_31408.ABSTRACTThe mere glimpse of venomous animals has always terrified humans because of the devastating effects of their venoms. However, researchers across the globe have isolated therapeutically active ingredients from these venoms and continue to explore them for drug leads. These efforts lead to the discovery of therapeutic molecules that the US-FDA has approved to treat different diseases, such as hypertension (Captopril), chronic pain (Ziconotide), and diabetes (Exenatide). The main active constituents of most venoms are proteins and p...
Source: Pharmacological Reviews - March 6, 2023 Category: Drugs & Pharmacology Authors: M A Morsy S Gupta C P Dora V Jhawat M Dhanawat D Mehta K Gupta A B Nair M El-Daly Source Type: research
Venoms classification and therapeutic uses: a narrative review
Eur Rev Med Pharmacol Sci. 2023 Feb;27(4):1633-1653. doi: 10.26355/eurrev_202302_31408.ABSTRACTThe mere glimpse of venomous animals has always terrified humans because of the devastating effects of their venoms. However, researchers across the globe have isolated therapeutically active ingredients from these venoms and continue to explore them for drug leads. These efforts lead to the discovery of therapeutic molecules that the US-FDA has approved to treat different diseases, such as hypertension (Captopril), chronic pain (Ziconotide), and diabetes (Exenatide). The main active constituents of most venoms are proteins and p...
Source: European Review for Medical and Pharmacological Sciences - March 6, 2023 Category: Drugs & Pharmacology Authors: M A Morsy S Gupta C P Dora V Jhawat M Dhanawat D Mehta K Gupta A B Nair M El-Daly Source Type: research
Prophylactic Agents for Preventing Cardiotoxicity Induced Following Anticancer Agents: A Systematic Review and Meta-Analysis of Clinical Trials
CONCLUSION: This meta-analysis showed that prophylactic treatment with cardio-protective drugs, including dexrazoxane, beta blocker, and ACEI drugs in patients undergoing chemotherapy with anthracycline, have a protective effect on LVEF and prevent EF drop.PMID:36803186 | DOI:10.2174/1574887118666230118102252 (Source: Reviews on Recent Clinical Trials)
Source: Reviews on Recent Clinical Trials - February 21, 2023 Category: Cancer & Oncology Authors: Ehsan Keshavarzian Tella Sadighpour Seyed Mohammadreza Mortazavizadeh Mohammadhossein Soltani Amir Farzin Motevalipoor Shahriyar Shahbazi Khamas Mohammad Moazen Mohamad Kogani Seyed Mohammad Amin Hashemipour Hamid Hosseinpour Rohollah Valizadeh Source Type: research
Prophylactic Agents for Preventing Cardiotoxicity Induced Following Anticancer Agents: A Systematic Review and Meta-Analysis of Clinical Trials
CONCLUSION: This meta-analysis showed that prophylactic treatment with cardio-protective drugs, including dexrazoxane, beta blocker, and ACEI drugs in patients undergoing chemotherapy with anthracycline, have a protective effect on LVEF and prevent EF drop.PMID:36803186 | DOI:10.2174/1574887118666230118102252 (Source: Reviews on Recent Clinical Trials)
Source: Reviews on Recent Clinical Trials - February 21, 2023 Category: Cancer & Oncology Authors: Ehsan Keshavarzian Tella Sadighpour Seyed Mohammadreza Mortazavizadeh Mohammadhossein Soltani Amir Farzin Motevalipoor Shahriyar Shahbazi Khamas Mohammad Moazen Mohamad Kogani Seyed Mohammad Amin Hashemipour Hamid Hosseinpour Rohollah Valizadeh Source Type: research
Impact of a change to a novel chemiluminescent immunoassay for measuring plasma aldosterone on the diagnosis of primary aldosteronism
Endocr J. 2023 Feb 16. doi: 10.1507/endocrj.EJ22-0585. Online ahead of print.ABSTRACTIn Japan, the standard method for measuring plasma aldosterone concentration (PAC) for primary aldosteronism (PA) diagnosis was changed from radioimmunoassay (RIA) to a novel chemiluminescent enzyme immunoassay (CLEIA). The purpose of this study is to simulate the possible impact of the change on PA diagnosis. This retrospective study assessed 2,289 PA patients. PACs measured by conventional RIA were transformed to estimated PACs (CLEIA) as follows: RIA (pg/mL) = 1.174 × CLEIA (pg/mL) + 42.3. We applied the estimated PAC (CLEIA) to the co...
Source: Endocrine Journal - February 15, 2023 Category: Endocrinology Authors: Hiroki Kobayashi Yoshihiro Nakamura Masanori Abe Akiyo Tanabe Masakatsu Sone Takuyuki Katabami Isao Kurihara Takamasa Ichijo Mika Tsuiki Shoichiro Izawa Norio Wada Takashi Yoneda Katsutoshi Takahashi Kouichi Tamura Yoshihiro Ogawa Nobuya Inagaki Koichi Ya Source Type: research
